Zhejiang Wecome Pharmaceutical (300878) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

300878 Zhejiang Wecome Pharmaceutical

Watchlist

20.57
+1.25+6.47%

Market Closed Dec 12 15:00 CST

2.98BMarket Cap-89.43P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Zhejiang Wecome Pharmaceutical (300878.SZ): Change of pharmaceutical production license.
November 13, GeLongHui丨Zhejiang Wecome Pharmaceutical (300878.SZ) announced that the company recently obtained the "pharmaceutical production license" issued by the Zhejiang Provincial Food and Drug Administration, agreeing to the application for change of the "pharmaceutical production license". This change mainly involves the change of the company's legal representative.
Gelonghui FinanceNov 13 03:55 ET
Weikang Pharmaceutical: Report for the third quarter of 2024
SZSIOct 27 12:00 ET · Announcements
Zhejiang Wecome Pharmaceutical (300878.SZ) released its performance for the first three quarters, with a net income of 44.1 million yuan, a year-on-year decrease of 36.41%.
zhejiang wecome pharmaceutical (300878.SZ) disclosed its third quarter report for 2024, achieving revenue of 3....
Zhitong FinanceOct 27 05:53 ET
Optimistic Investors Push Zhejiang Wecome Pharmaceutical Company Limited (SZSE:300878) Shares Up 39% But Growth Is Lacking
Simply Wall StOct 8 20:13 ET
Wecome Pharmaceutical Amends Drug Production License
MT NewswiresSep 27 05:52 ET
Weikang Pharmaceutical: 2024 Semi-Annual Report
SZSIAug 29 12:00 ET · Announcements

Comments

Moomoo AI

Mar 8 17:25

High P/S ratio could be justified if the company outperforms the industry. However, with declining revenue and predicted industry growth, the current share price may not be sustainable. Unless conditions improve significantly, shares may be overvalued.

Zhejiang Wecome Pharmaceutical Company Limited (SZSE:300878) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Moomoo AI

Jan 22 23:03

Zhejiang Wecome Pharmaceutical's high P/S ratio is alarming considering its recent revenue drop. This trend could jeopardize shareholders' investments and deter potential investors. The share price might decrease, making the P/S more reasonable.

Some Shareholders Feeling Restless Over Zhejiang Wecome Pharmaceutical Company Limited's (SZSE:300878) P/S Ratio

Moomoo AI

Dec 12, 2023 17:14

Despite Zhejiang Wecome Pharmaceutical's stock rise, the company's performance appears uncertain with low ROE and decline in net income over the past five years. Investors may not be benefitting from the reinvestment of profits due to low earnings growth.